Erratum to: A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX^®

Erratum to: Osteoporos Int

DOI 10.1007/s00198-010-1474-0

An error occurred in this publication due to the incorrect computation of the hazard ratio (HR) for the effects of strontium ranelate. Treatment with strontium ranelate was associated with a decrease in the risk of a clinical vertebral fracture compared with placebo (HR = 0.75; 95% confidence interval 0.62–0.92). In the original publication the HR was given as 0.50 (95% CI 0.41–0.60). The error does not affect the overall interpretation of the data or conclusions but alters the numerical values given in Tables 3, 4, 5, 6. The corrected tables are given below.

Table 3 The relationship of incident fracture (fractures/100 patient years) in placebo-treated patients by quartiles of fracture probability

Table 4 Overall effects of strontium ranelate compared to placebo according to the fracture outcome selected

Table 5 Hazard ratio between treatments (strontium ranelate versus placebo) for all clinical osteoporotic fractures at different values of 10 year probability (%) of a major osteoporotic fracture calculated with and without BMD

Table 6 Hazard ratio between treatments (strontium ranelate versus placebo) for hip fracture and for clinical vertebral fracture at different percentiles of 10 year probability (%) of a major osteoporotic fracture calculated with BMD